Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 8.17B +26.7% |
| Revenue (ttm) | 2.59B +1.9% |
| Net Income | 168.80M |
| EPS | 6.24 |
| Shares Out | 26.76M |
| PE Ratio | 48.94 |
| Forward PE | 34.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 442,211 |
| Open | 311.10 |
| Previous Close | 312.48 |
| Day's Range | 304.84 - 311.10 |
| 52-Week Range | 211.43 - 343.12 |
| Beta | 1.06 |
| Analysts | Hold |
| Price Target | 297.00 (-2.77%) |
| Earnings Date | Apr 30, 2026 |
About BIO
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BIO stock is "Hold." The 12-month stock price target is $297.0, which is a decrease of -2.77% from the latest price.
News
Bio-Rad price target raised to $310 from $290 at Wells Fargo
Wells Fargo raised the firm’s price target on Bio-Rad (BIO) to $310 from $290 and keeps an Equal Weight rating on the shares after meeting with management. The macro environment…
Bio-Rad Laboratories Transcript: RBC Capital Markets Global Healthcare Conference 2026
Digital PCR instruments saw 24% growth, led by the QX700 series, and quality controls remain a global growth focus with attractive margins. Regional challenges in the Middle East and softness in early-stage biopharma are offset by stable China operations and new local manufacturing. Margin expansion and operational efficiencies are key near-term priorities.
Activist Elliott Takes Major Stake in Bio-Rad — Can It Boost BIO Stock Price?
Activist investor Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories ($BIO). According to the Wall Street Journal, Elliott is aiming to push management to impro...
Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports
Activist investor Elliott Investment Management has built a sizeable stake in U.S. diagnostics supplier Bio-Rad Laboratories , and plans to push the company to boost its underperforming stock price,...
Activist investor Elliot builds big stake in Bio-Rad, WSJ says
Activist investor Elliot Investment Management has built a big stake in Bio-Rad (BIO)e Laboratories, with plans to push the company to boost its underperforming stock price, Lauren Thomas of The…
Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad
Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.
Bio-Rad resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Bio-Rad (BIO) with an Outperform rating and $320 price target The company’s sales growth should recover in 2027 following “idiosyncratic product headwinds” in 2026, the...
Bio-Rad to Participate in Upcoming Investor Conferences
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will p...
Bio-Rad price target lowered to $290 from $320 at Wells Fargo
Wells Fargo lowered the firm’s price target on Bio-Rad (BIO) to $290 from $320 and keeps an Equal Weight rating on the shares. The firm notes Q1 missed on organic…
Bio-Rad Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 revenue was within guidance despite a significant Middle East impact, with flat life science sales and modest diagnostics growth. Guidance was lowered for 2026, reflecting ongoing geopolitical and funding headwinds, but operational and innovation initiatives continue to drive long-term positioning.
Bio-Rad Laboratories Earnings release: Q1 2026
Bio-Rad Laboratories released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Bio-Rad Laboratories Quarterly report: Q1 2026
Bio-Rad Laboratories has published its Q1 2026 quarterly earnings report on April 30, 2026.
Bio-Rad Laboratories Slides: Q1 2026
Bio-Rad Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Bio-Rad reports Q1 EPS $1.89, consensus $1.99
Reports Q1 revenue $592.1M, consensus $588.86M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, stated: “Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite...
Bio-Rad Reports First-Quarter 2026 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad downgraded to Neutral from Buy at Citi
Citi analyst Patrick Donnelly downgraded Bio-Rad (BIO) to Neutral from Buy with a price target of $300, down from $375. The firm does not see a recovery path for the…
Bio-Rad downgraded to Neutral from Buy at Citi
Citi analyst Patrick Donnelly downgraded Bio-Rad (BIO) to Neutral from Buy with a $300 price target
Bio-Rad Laboratories Proxy statement: Proxy filing
Bio-Rad Laboratories filed a proxy statement on March 25, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Rad price target lowered to $320 from $340 at Wells Fargo
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Bio-Rad (BIO) to $320 from $340 and keeps an Equal Weight rating on the shares. The firm contends that…
Bio-Rad price target lowered to $335 from $350 at UBS
UBS lowered the firm’s price target on Bio-Rad (BIO) to $335 from $350 and keeps a Buy rating on the shares. While there were some bright spots, margins were “messy,”…
Bio-Rad Laboratories Earnings Call Transcript: Q4 2025
Q4 and full year 2025 results met revised revenue and operating margin guidance, but gross margin was pressured by supply chain costs. Diagnostics returned to growth, ddPCR saw strong QX700 sales, and free cash flow was robust. 2026 guidance calls for modest revenue growth and margin improvement.
Bio-Rad Laboratories Annual report: Q4 2025
Bio-Rad Laboratories has published its Q4 2025 annual report on February 12, 2026.